Clinical Study on Artieral Infusion Chemotherapy Combined with <sup>125</sup>I Seed Implantation in Treatment of NSCLC_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

RenWeichao ,  SunChengjian , WangYanhua , LiuTonghui , ZhaoXiaolong , WangHongyu

Department of Interventional Radiology, The Affliated Hospital of Qingdao University, Qingdao, Shandong, 266003, China;

Corresponding?author：

SunChengjian, Email: chengjiansun2009@163.com

Keywords：

Non-small cell lung cancer; ¹²⁵I seed implantation; Artieral infusion; Chemotherapy

DOI：

10.7507/1671-6205.2016060

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the clinical efficacy and safety of artieral infusion chemotherapy combined with ¹²⁵I seed implantation in treatment of non-small cell lung cancer (NSCLC). Methods Between February 2012 to June 2014, 34 patients with unresectable NSCLC received ¹²⁵I seed implantation, in which 16 patients also received artieral infusion chemotherapy. All the patients were followed up and two months after ¹²⁵I seed implantation the thoracic CT scanning was carried out in all patients. The response to treatment was evaluated in accordance with Response Evaluation Criteria in Solid Tumors and the accumulated survival rate was analyzed by means of Kaplan-Meier. Results The operation successful rate was 100% and no severe complications were observed. Two months later the thoracic CT scanning showed that patients who only received ¹²⁵I seed implantation with a total effective rate of 72.2% and those received artieral infusion chemotherapy combined with ¹²⁵I seed implantation with an effective rate of 87.5%, with no significant difference between two groups in the effective rate (χ²=1.122, P>0.05). Median survival time of two groups was 361 days and 470 days (χ²=2.985, P < 0.05), respectively. Survival rate of 1 year was 43.5% and 83.5%(χ²=4.101, P < 0.05), respectively. Conclusion Artieral infusion chemotherapy combined with ¹²⁵I seed implantation is safe, reliable and effective in treatment of unresectable NSCLC, which can prolong the patient's survival time.

Citation： Ren Weichao, Sun Chengjian, Wang Yanhua, Liu Tonghui, Zhao Xiaolong, Wang Hongyu. Clinical Study on Artieral Infusion Chemotherapy Combined with ¹²⁵I Seed Implantation in Treatment of NSCLC. Chinese Journal of Respiratory and Critical Care Medicine, 2016, 15(3): 256-260. doi: 10.7507/1671-6205.2016060 Copy

1.	Cady B, Jenkins RL, Steele GD Jr, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg, 1998, 227:566-571.
2.	Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45: 228-247.
3.	Hoffman PC, Mauer AM, Yokes EE. Lung cancer. Lancet, 2000, 355:479-485.
4.	Nesbitt JC, Putnam JB Jr., Walsh GL, et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg, 1995, 60:466-472.
5.	Rami-Porta R, Ball D, Crowley J, et al. The lASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol, 2007, 2:593-602.
6.	儲水鑫.肺癌放療并發癥的中藥治療.中國中西醫結合外科雜志, 2011, 12:645.
7.	李任飛, 王月東, 閆龑, 等.¹²⁵I粒子植入治療非小細胞肺癌近期療效評估.介入放射學雜志, 2014, 23:65-68.
8.	趙明星, 劉文天, 王邦茂, 等.近距離放射治療在消化系腫瘤治療中的應用前景.國際消化雜志, 2013, 33:160-179.
9.	李忠福, 蘇東峰, 張延軍, 等.支氣管動脈灌注化療與全身靜脈化療治療中晚期肺癌療效觀察.中國介入放射學, 2008, 2:327-329.
10.	王忠敏, 黃鋼, 陳克敏, 等.放射性粒子組織間植入治療技術指南的建議.介入放射學雜志, 2009, 18:641-644.
11.	Dubben HH, Beck-Bornholdt HP. Influence of the timing of a concomitant boost during fractionated irradiation of rat rhabdomyosarcoma R1H. Acta Oncol, 1993, 32:79-82.
12.	Durand RE. Tumor repopulation during radiotherapy: quantitation in two xenografted human tumors. Int J Radiat Oncol Biolphys, 1997, 39: 803-808.
13.	Fietkau R. Concomitant radio chemotherapy of advanced non-small cell lung cancer. Lung Cancer, 2001, 33:65-76.
14.	曹貴文, 李學達, 孫莉寧, 等.¹²⁵I放射性粒子植入對兔肝癌微血管密度及血管內皮生長因子的影響.當代醫學, 2011, 17:108-112.
15.	Johnson M, Colonias A, Parda D, et al. Dosimetric and technical aspects of intraoperative I-125 brachytherapy for stage Ⅰ non-small cell lung cancer. Phys Med Biol, 2007, 52:1237-1245.
16.	Nakanishi M, Umeda Y, Demura Y, et al. Effective use of multi-arterial infusion chemotherapy for advanced non-small cell cancer patients:four clinical specified cases. Lung Cancer, 2007, 55:241-247.
17.	Sura S, Yorke E, Jackson A, et al. High-dose radiotherapy for the treatment of inoperable non-mall cell lung cancer. Cancer, 2007, 19:238-242.
18.	趙書元.¹²⁵I粒子植入聯合支氣管動脈灌注化療治療中晚期肺癌的臨床研究.中國醫藥指南, 2013, 11:87-88.
19.	鞠再雙, 王林, 李建新, 等.¹²⁵I粒子植入犬胃壁組織放射性損傷的實驗研究.中國微創外科雜志, 2014, 14:468-471.

1. Cady B, Jenkins RL, Steele GD Jr, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg, 1998, 227:566-571.
2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45: 228-247.
3. Hoffman PC, Mauer AM, Yokes EE. Lung cancer. Lancet, 2000, 355:479-485.
4. Nesbitt JC, Putnam JB Jr., Walsh GL, et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg, 1995, 60:466-472.
5. Rami-Porta R, Ball D, Crowley J, et al. The lASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol, 2007, 2:593-602.
6. 儲水鑫.肺癌放療并發癥的中藥治療.中國中西醫結合外科雜志, 2011, 12:645.
7. 李任飛, 王月東, 閆龑, 等.¹²⁵I粒子植入治療非小細胞肺癌近期療效評估.介入放射學雜志, 2014, 23:65-68.
8. 趙明星, 劉文天, 王邦茂, 等.近距離放射治療在消化系腫瘤治療中的應用前景.國際消化雜志, 2013, 33:160-179.
9. 李忠福, 蘇東峰, 張延軍, 等.支氣管動脈灌注化療與全身靜脈化療治療中晚期肺癌療效觀察.中國介入放射學, 2008, 2:327-329.
10. 王忠敏, 黃鋼, 陳克敏, 等.放射性粒子組織間植入治療技術指南的建議.介入放射學雜志, 2009, 18:641-644.
11. Dubben HH, Beck-Bornholdt HP. Influence of the timing of a concomitant boost during fractionated irradiation of rat rhabdomyosarcoma R1H. Acta Oncol, 1993, 32:79-82.
12. Durand RE. Tumor repopulation during radiotherapy: quantitation in two xenografted human tumors. Int J Radiat Oncol Biolphys, 1997, 39: 803-808.
13. Fietkau R. Concomitant radio chemotherapy of advanced non-small cell lung cancer. Lung Cancer, 2001, 33:65-76.
14. 曹貴文, 李學達, 孫莉寧, 等.¹²⁵I放射性粒子植入對兔肝癌微血管密度及血管內皮生長因子的影響.當代醫學, 2011, 17:108-112.
15. Johnson M, Colonias A, Parda D, et al. Dosimetric and technical aspects of intraoperative I-125 brachytherapy for stage Ⅰ non-small cell lung cancer. Phys Med Biol, 2007, 52:1237-1245.
16. Nakanishi M, Umeda Y, Demura Y, et al. Effective use of multi-arterial infusion chemotherapy for advanced non-small cell cancer patients:four clinical specified cases. Lung Cancer, 2007, 55:241-247.
17. Sura S, Yorke E, Jackson A, et al. High-dose radiotherapy for the treatment of inoperable non-mall cell lung cancer. Cancer, 2007, 19:238-242.
18. 趙書元.¹²⁵I粒子植入聯合支氣管動脈灌注化療治療中晚期肺癌的臨床研究.中國醫藥指南, 2013, 11:87-88.
19. 鞠再雙, 王林, 李建新, 等.¹²⁵I粒子植入犬胃壁組織放射性損傷的實驗研究.中國微創外科雜志, 2014, 14:468-471.

Chinese Journal of Respiratory and Critical Care Medicine

Clinical Study on Artieral Infusion Chemotherapy Combined with ¹²⁵I Seed Implantation in Treatment of NSCLC

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

Chinese Journal of Respiratory and Critical Care Medicine

Clinical Study on Artieral Infusion Chemotherapy Combined with 125I Seed Implantation in Treatment of NSCLC

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

Clinical Study on Artieral Infusion Chemotherapy Combined with ¹²⁵I Seed Implantation in Treatment of NSCLC